Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3060 | Prazosin Wiki | 0.71 |
| drug3738 | Standard of care Wiki | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Patients suffering from pneumonia due to SARS-CoV-2 infection, after admission to the Intensive Care Unit (ICU), are susceptible to development of various functional sequelae, increased risk of chronic diseases, increased mortality rates and existence of relevant impacts on their quality of life in the months and years that follow the ICU admission. The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among patients recovered from SARS-COV-2 pneumonia, after discharge from the ICU, its determinants and predictors, in Portugal. It is a multicenter prospective cohort study of adult patients admitted at the ICU due to proven or suspected SARS-CoV-2 infection, included 90 days after discharge from the ICU. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. The secondary outcomes are all-cause mortality, rehospitalizations, return to work or study, the degree of dependence and functional capacity, symptoms of anxiety, depression and post-traumatic stress, level of physical activity and cognitive, renal and respiratory functions after ICU discharge. Investigators will collect data by means of structured telephone interviews, at a 12 months follow up period.
Description: The outcome will be assessed using the Portuguese version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).
Measure: Health-related quality of life. Time: One-year (12 months) after ICU discharge.Description: Length of stay at the ICU.
Measure: Length of stay at the ICU. Time: The outcome will be assessed 3 months after ICU discharge (at the participant enrollment).Description: Incidence of all-cause mortality.
Measure: Incidence of all-cause mortality Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: Rehospitalization.
Measure: Rehospitalization. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: Percentage of patients requiring oxygen therapy, non-invasive ventilation, or mechanical ventilation.
Measure: Percentage of long-term ventilatory support need. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: Percentage of patients requiring any kind of renal replacement therapy.
Measure: Percentage of renal replacement therapy need. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: The outcome will be assessed using the Hospital Anxiety and Depression Scale (anxiety and depression scores range from 0 to 21, with higher scores indicating worse symptoms).
Measure: Symptoms of anxiety and depression. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: The outcome will be assessed using the Lawton & Brody Instrumental Activities of Daily Living Scale, a score of instrumental activities of daily living (the score ranges from 0 to 8, with higher scores indicating less dependence).
Measure: Score of functional independence. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: The outcome will be assessed using the The Montreal Cognitive Assessment (MoCA). The score ranges from 0 to 30, in 8 domains, with higher scores indicating worse symptoms.
Measure: Score of cognitive function. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: Percentage of major cardiac events.
Measure: Percentage of major cardiac events. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: Score of Chronic obstructive pulmonary disease (COPD) assessed using the Portuguese version of the Clinical COPD Questionnaire (CCQ). The Clinical COPD, consisting of 10 items (each scored between 0 and 6), divided into three domains (symptoms, functional, mental). The total score is calculated by summing the scores of the individual items and dividing by 10 (the number of individual items) giving a total score between 0 and 6 with higher scores representing worse scenario.
Measure: Score of Chronic obstructive pulmonary disease (COPD) Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: The outcome will be assessed using the Impact Event Scale-Revised (the score ranges from 0 to 88, with higher scores indicating worse symptoms).
Measure: Symptoms of posttraumatic stress disorder Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: The outcome will be assessed using the Portuguese version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).
Measure: Utility score of health-related quality of life at 3, 6, and 9 months. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Description: The outcome will be assessed using the visual analogue scale of the Portuguese version of the Euroqol-5D-3L questionnaire (EQ-VAS; score range from o to 100, with higher scores indicating better self-rated health).
Measure: Score of self-rated health. Time: The outcome will be assessed at 3, 6, 9 and 12 months after ICU discharge.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports